Loading...
•
Dec 31, 2022
LivaNova Q4 2022 Earnings Report
LivaNova's Q4 2022 performance reflected revenue growth across all regions, driven by Cardiopulmonary and Neuromodulation business units, with GAAP EPS of $0.03 and adjusted EPS of $0.81.
Key Takeaways
LivaNova PLC reported a 1.8% increase in fourth-quarter revenue, reaching $274.9 million, and a U.S. GAAP diluted earnings per share of $0.03. The company experienced growth across all regions, particularly in the Cardiopulmonary and Neuromodulation business units. Adjusted diluted earnings per share were $0.81.
Fourth-quarter revenue increased 1.8% on a reported basis and 6.2% on a constant-currency basis.
U.S. GAAP diluted earnings per share was $0.03 and adjusted diluted earnings per share was $0.81.
Completed first clinical cases using EssenzTM at two major centers in Europe.
Received ECMO indication 510(k) clearance for LifeSPARCTM.
LivaNova
LivaNova
LivaNova Revenue by Segment
Revenue by Segment
Cardiopulmonary Revenue
CapyFin.comNeuromodulation Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
LivaNova expects revenue for full-year 2023 to grow between 3 and 5 percent on a constant-currency basis. Adjusted diluted earnings per share for 2023 are expected to be in the range of $2.45 to $2.65, assuming a share count of 54 million for full-year 2023. In 2023, the Company estimates that adjusted free cash flow will be in the range of $80 to $100 million.
Positive Outlook
- Revenue for full-year 2023 to grow between 3 and 5 percent on a constant-currency basis.
- Foreign currency is expected to be a 1 percent tailwind.
- Adjusted diluted earnings per share for 2023 are expected to be in the range of $2.45 to $2.65.
- Share count of 54 million for full-year 2023.
- Adjusted free cash flow will be in the range of $80 to $100 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income